1 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow AB8939: new trials by email Literature Review of AB8939 trials Research Report on AB8939
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia AB8939, Venetoclax - Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse | Phase 1 / Phase 2 | Recruiting | AB Science | 78 | 2022-06-01 | 2025-10-02 |
GATA2 Deficiency (1) · Leukemia, Myeloid, Acute (1)
AB Science (1)
France (1) · Greece (1) · Spain (1) · United States (1)
Nicholas Short, MD (1) · Norbert Vey, MD (1)